Viatris
VTRS
$0.13 (-1.23%)
1D
1W
3M
1Y
5Y
ALL
Viatris Inc. is a global healthcare company. The Company has four segments: Developed Markets, Greater China, JANZ and Emerging Markets. Developed Markets segment comprises its operations primarily in North America and Europe. Greater China segment includes its operations in China, Taiwan and Hong Kong. JANZ segment reflects its operations in Japan, Australia and New Zealand. Emerging Markets segment encompasses its presence in approximately 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as its anti-retroviral franchise. Its portfolio comprises approximately 1,400 approved molecules across a range of key therapeutic areas, including globally recognized iconic and key brands, generics, complex generics, and biosimilars. It operates approximately 40 manufacturing sites worldwide, which produces oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
PRNewsWire • 7 days ago • VTRS
Viatris Publishes 2023 Sustainability Report: Building Sustainable Access at ScaleGlobeNewsWire • 7 days ago • VTRS
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigorZacks Investment Research • 19 days ago • VTRS
Viatris' (VTRS) Q1 Earnings & Sales Lag Estimates, Stock DownZacks Investment Research • 19 days ago • VTRS
Viatris (VTRS) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 19 days ago • VTRS
Viatris (VTRS) Q1 Earnings and Revenues Miss EstimatesCharts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.